CeO 2 -Azacrown Conjugate as a Nanoplatform for Combined Radiopharmaceuticals.

Sofia Khabirova Gleb Yu AleshinTatiana PlakhovaAnastasia ZubenkoAnna A ShchukinaOlga FedorovaAleksey AverinEkaterina BelovaElena BazarkinaKristina KvashninaStepan Kalmykov

Published in: Nanomaterials (Basel, Switzerland) (2022)

This study is one of the first attempts to assess CeO 2 nanoparticles as a nanoplatform for radiopharmaceuticals with radionuclides. The process of functionalization using a bifunctional azacrown ligand is described, and the resulting conjugates are characterized by IR and Raman spectroscopy. Their complexes with 207 Bi show a high stability in medically relevant media, thus encouraging the further study of these conjugates in vivo as potential combined radiopharmaceuticals.

Keyphrases

cancer therapy
raman spectroscopy
photodynamic therapy
drug delivery
drug release
risk assessment
human health